Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GRWD5769 alone and with cemiplimab in solid malignancies
2023-504845-30-00Phase 2Authorised
- Sponsor
- Grey Wolf Therapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of GRWD5769 in Non-hematologic malignancy, Cervical Cancer (CC), hepatocellular carcinoma (HCC) and 7 more (3 arms), sponsored by Grey Wolf Therapeutics. Primary endpoints: Treatment-emergent and treatment-related adverse events, Dose-limiting toxicities and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
GRWD5769
03
Conditions
Non-hematologic malignancyCervical Cancer (CC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504845-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504845-30-00.